PDF(Pubmed)
Abstract：
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer were updated and published online in 2023, and adapted, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with early breast cancer. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with breast cancer representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and KSMO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with early breast cancer across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling, as well as the age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.
摘要：
欧洲医学肿瘤学会（ESMO）诊断的临床实践指南，2023年更新并在线发表早期乳腺癌患者的治疗和随访，根据以前建立的标准方法，为亚洲早期乳腺癌患者的管理制定泛亚适应（PAGA）ESMO共识指南。本手稿中提出的适应指南代表了代表中国肿瘤学会（CSCO）的亚洲专家小组在治疗乳腺癌患者方面达成的共识意见。印度尼西亚(ISHMO)，印度(ISMPO),日本(JSMO),韩国(KSMO),马来西亚(MOS),菲律宾（PSMO）新加坡(SSO),台湾（TOS）和泰国（TSCO），由ESMO和KSMO协调。投票基于科学证据，独立于当前的治疗实践，10个肿瘤学会代表的亚洲地区的药物获取限制和报销决定。后者在手稿中单独讨论。目的是为亚洲不同地区早期乳腺癌患者的管理优化和协调提供指导，借鉴西方和亚洲试验提供的证据，在尊重筛查实践差异的同时，分子谱分析,以及演讲的年龄和阶段。提请注意药物批准和报销策略的差异，在亚洲不同地区之间。
